Overview
Gonadorelin is a synthetic decapeptide identical in structure to endogenous gonadotropin-releasing hormone (GnRH), produced naturally by the hypothalamus. It is FDA-approved and used clinically to stimulate the pituitary gland, maintain testicular function in men on testosterone replacement therapy, treat hypogonadotropic hypogonadism, and support fertility. It is administered in pulsatile protocols to mimic natural hormonal signaling.
Mechanism of action
Gonadorelin binds to GnRH receptors on pituitary gonadotrope cells, triggering the synthesis and pulsatile release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH stimulates Leydig cells in the testes to produce testosterone, while FSH supports Sertoli cells and spermatogenesis. The pulsatile pattern is critical — continuous administration causes receptor downregulation and desensitization, paradoxically suppressing gonadotropin output (the basis of GnRH agonist-based androgen deprivation therapy). When dosed correctly in pulses every 60–120 minutes, gonadorelin preserves the hypothalamic-pituitary-gonadal (HPG) axis feedback loop, maintaining intratesticular testosterone and sperm production even in men receiving exogenous testosterone.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| TRT testicular maintenance | subcutaneous | 100–100 mcg | 2-3x per week | Inject subcutaneously. Goal is LH/FSH stimulation to preserve testicular size and intratesticular testosterone on TRT. |
| Hypogonadotropic hypogonadism / fertility | subcutaneous | 5–20 mcg | Pulsatile, every 90-120 minutes via infusion pump | Delivered via portable infusion pump. Pulsatile dosing is essential — continuous exposure suppresses rather than stimulates. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Gonadorelin has an extensive clinical evidence base as an FDA-approved diagnostic and therapeutic agent. In TRT protocols, it is used off-label to prevent testicular atrophy by preserving LH and FSH signaling. Studies show pulsatile GnRH delivery restores fertility in men with hypogonadotropic hypogonadism. Research confirms that 100 mcg subcutaneous doses two to three times weekly can partially preserve testicular volume and intratesticular testosterone compared to TRT-only protocols, though evidence for full fertility preservation on concurrent TRT is mixed.
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Gonadorelin for synergistic effects.
Legal status
FDA-approved for diagnostic evaluation of pituitary function and treatment of primary hypothalamic amenorrhea and hypogonadotropic hypogonadism. Used off-label in TRT protocols via compounding pharmacies. Lutrepulse (pump-delivered gonadorelin) was FDA-approved for ovulation induction. Available through licensed compounding pharmacies in injectable form.
Where to get it
Prescription required
Gonadorelin is a prescription medication. Consult your healthcare provider or a licensed telehealth platform for access.